Outcomes in people with HIV who resume or switch to bictegravir/emtricitabine/tenofovir alafenamide following a treatment interruption
High levels of suppression following treatment interruption may suggest B/F/TAF regimen forgiveness making it an appropriate choice for treatment switch or restart.
Authors
- Paul E. Sax (ORCID: https://orcid.org/0000-0001-8434-174X)
- Andrew Frick (ORCID: https://orcid.org/0000-0003-2700-9382)
- Janna Radtchenko (ORCID: https://orcid.org/0000-0002-0462-5505)
- Travis Lim (ORCID: https://orcid.org/0000-0003-1662-7329)
- Paul Benson
- Richard Elion
- Joshua Gruber
- Megan Dunbar
- Andrea Marongiu (ORCID: https://orcid.org/0000-0001-7038-3615)
- Graeme Moyle (ORCID: https://orcid.org/0000-0002-2395-3774)
- Steven Santiago
- Charles Walworth
Institutions
- Brigham and Women's Hospital (US)
- KentuckyOne Health (US)
- Chelsea and Westminster Hospital (GB)
- Gilead Sciences (United States) (US)
- Care Resource (US)
- Alta Bates Summit Medical Center (US)
Publication Details
- Journal
- AIDS
- Published
- 2025-03-06
- DOI
- https://doi.org/10.1097/qad.0000000000004171
- Citations
- 1
- Primary Topic
- HIV/AIDS drug development and treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.40